The misuse of synthetic opioids: harms and clinical management of fentanyl, fentanyl analogues and other novel synthetic opioids - Information for clinicians Dima Abdulrahim and Owen Bowden-Jones on behalf of the NEPTUNE group London, 2018, NE...

Fentanyl - ein unkalkulierbares Risiko In dieser Kurzinformation Nr. 13 "Fentanyl - ein unkalkulierbares Risiko" informieren wir über die Substanz Fentanyl, die Risiken des Konsums sowie über Maßnahmen der Schadensminderung. (DAH ...

EMCDDA–Europol Joint Report on a new psychoactive substance: 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) (EMCDDA, Europol, Lissabon, Februar 2018) http://www.emcdda.europa.eu/publications/joint-r...

EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) (EMCDDA, Europol, Lissabon, Februar 2018) http://www.emcdda.europa.eu/publications/join...

An Expanding World of Novel Psychoactive Substances: Opioids. Zawilska JB. Front Psychiatry. 2017 Jun 30;8:110. doi: 10.3389/fpsyt.2017.00110. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492455/

Vancouver Study: 100% of Opioid-Users Tested Positive for Fentanyl MedicalResearch.com Interview with: William G. Honer, MD, FRCPC, FCAHS (Jack Bell Chair in Schizophrenia; Professor and Head, Department of Psychiatry, University of British Colum...